Phaseline

Companies › Hexaell Biotech

Hexaell Biotech: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Infectious disease.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HepaCure
hiHep cell-based bio-artificial liver support system
–Phase 1Acute on Chronic Hepatic Failure–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05989958HepaCurePhase 1Acute on Chronic Hepatic FailureInfectious diseaseSep 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.